Foresite Capital Management II’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Foresite Capital Management II’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-523,132	Closed	-$1.11M	–	15
2017 Q3	$1.11M	Sell	523,132 -78,881	-13%	-$192K	0.45%	11
2017 Q2	$1.75M	Sell	602,013 -20,000	-3%	-$60K	0.8%	7
2017 Q1	$2.14M	Buy	622,013 +79,258	+15%	+$313K	0.92%	9
2016 Q4	$944K	Hold	542,755	–	–	0.47%	8
2016 Q3	$1.8M	Sell	542,755 -1	-0%	-$4	0.86%	9
2016 Q2	$2.33M	Sell	542,756 -103,452	-16%	-$468K	1.6%	11
2016 Q1	$3.64M	Buy	646,208 +23,703	+4%	+$308K	1.78%	13
2015 Q4	$10.7M	Buy	622,505 +200,000	+47%	+$4.77M	3.59%	9
2015 Q3	$8.91M	Buy	422,505 +2,500	+0.6%	+$85.7K	2.71%	11
2015 Q2	$20.8M	Hold	420,005	–	–	7.3%	6
2015 Q1	$32.9M	Buy	420,005 +18,238	+5%	+$1.13M	19.48%	2
2014 Q4	$24.3M	Buy	+401,767	New	+$20.2M	16.67%	2

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Foresite Capital Management II's OREX Position: Q4 2017 in Review

Foresite Capital Management II sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2017, closing a stake of 523,132 shares — an estimated $1.11M sold.

Foresite Capital Management II first reported a position in OREX in Q4 2014 and held it in 12 quarters. The position peaked at $32.9M in Q1 2015. 41 funds tracked by Wall St. Rank hold OREX as of Q4 2017.

Foresite Capital Management II reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Foresite Capital Management II sold 523,132 Orexigen Therapeutics, Inc. shares in Q4 2017, an estimated $1.11M.
Foresite Capital Management II first reported a position in Orexigen Therapeutics, Inc. in Q4 2014 and held it in 12 quarters.
Foresite Capital Management II's Orexigen Therapeutics, Inc. position peaked at $32.9M in Q1 2015.
41 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2017.

Based on Foresite Capital Management II's 13F filing for Q4 2017, filed 13 Feb 2018.